4.8.6.5Vertical
Prescription Hearing Aids
FDA-regulated prescription hearing aids dispensed through audiologists and ENT practices, ranging from basic amplification to advanced AI-powered and rechargeable devices.
Market snapshot
These figures describe Hearing Devices & Cochlear Implants (4.8.6), the segment that Prescription Hearing Aids sits within — not Prescription Hearing Aids on its own.
FragmentationConsolidatedEstimate
Within electromedical apparatus (NAICS 334510) and surgical appliances (339113); the Census Bureau does not split out hearing devices, so the segment is not separately sized.
Business model & economics
Revenue model
Device sales through audiology, retail, and OTC channels
Key economics
- Recurring revenue
- Moderate
- EBITDA margin
- 18–28%
- Capex intensity
- High
replacement cycles and accessories
Characteristics
- Hearing aids a consolidated global oligopoly.
- OTC authorization opened a consumer channel.
- Aging-related hearing loss drives demand.
M&A deal context
Deal activityModerate
Who’s acquiring
- Hearing-device strategics
- Consumer-audio & OTC entrants
- Audiology-retail consolidators
What’s driving deals
- OTC hearing-aid channel disruption.
- Aging-related hearing-loss demand.
- Consolidation of audiology distribution.
Find Prescription Hearing Aids acquisition targets
Search Acquisera’s index for companies classified under Prescription Hearing Aids (4.8.6.5) and build a targeted deal pipeline.
Search companies